卖什么
Full Stack Pharmaceutical Company for Personalized Peptides and GLP-1s
商业模式拆解
买家：谁掌握预算？
未核实Patients pay directly (no insurance required); prescribing doctors and clinics are the partner/channel.
触发点：什么让他们现在购买？
未核实Consumers want GLP-1/peptide therapy (e.g. tirzepatide) online at a lower cash price without insurance.
工作流：什么输入变成什么输出？
Patient completes online intake, a licensed doctor sets the dose and prescribes, a partnered pharmacy compounds and validates the medication, and it ships directly to the patient with free two-day shipping; refills are paced with the doctor.
经济账：省了什么，怎么收费？
Monthly cash-pay subscriptions per medication (e.g. tirzepatide shown as $78/month, struck from $195); also sells platform access to doctors and clinics so they can run personalized-medicine programs without building pharmacy infrastructure.
渠道：怎么接触到客户？
Direct-to-consumer online funnel with an AI text assistant, plus a "Request partnership call" channel for doctors and clinics.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2026 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.